Trials / Completed
CompletedNCT00530699
Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)
A Phase I, Open Label, Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD1152 in Japanese Patients With Acute Myeloid Leukaemia.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess safety and tolerability of multiple ascending doses of AZD1152 and to assess effect of AZD1152 on the rate of complete remission in patients with relapsed acute myeloid leukaemia who are not considered to be suitable for standard chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD1152 | intravenous |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2007-09-17
- Last updated
- 2009-09-11
Locations
7 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00530699. Inclusion in this directory is not an endorsement.